These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. Spisarová M; Melichar B; Vitásková D; Študentová H Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744 [No Abstract] [Full Text] [Related]
11. Immunotherapy for kidney cancer: status quo and the future. Bedke J; Stühler V; Stenzl A; Brehmer B Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911 [TBL] [Abstract][Full Text] [Related]
12. Recent advances and future directions in the management of metastatic renal cell carcinoma. Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547 [TBL] [Abstract][Full Text] [Related]
13. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385 [TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy for Metastatic Renal Cell Carcinoma. Afriansyah A; Hamid AR; Mochtar CA; Umbas R Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997 [TBL] [Abstract][Full Text] [Related]
15. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Gill DM; Hahn AW; Hale P; Maughan BL Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125 [TBL] [Abstract][Full Text] [Related]
16. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844 [TBL] [Abstract][Full Text] [Related]
17. T-cell checkpoint inhibitors in metastatic renal cell carcinoma. Grünwald V Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506 [TBL] [Abstract][Full Text] [Related]
18. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Rizzo A; Rosellini M; Marchetti A; Mollica V; Massari F Immunotherapy; 2021 Jun; 13(8):685-692. PubMed ID: 33823678 [TBL] [Abstract][Full Text] [Related]
19. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031 [TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy for renal cell carcinoma - current status]. Grimm MO; Foller S Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]